๐ฐ Multiple Sclerosis Centers News
Page 3 - Multiple Sclerosis Centers News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple Sclerosis Centers. Real-time updates on events, politics, business and more.
June 1, 2023
NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023
May 31, 2023
(RTTNews) - French drug major Sanofi S.A. (SNYNF, SNY) announced Wednesday positive Phase 2 data of novel investigational anti-CD40L antibody frex...
May 31, 2023
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary
May 31, 2023
The Consortium of Multiple Sclerosis Centers has recently announced new initiatives to address disparities and inequality in MS care.
May 31, 2023
31.05.2023 - NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) - TG Therapeutics, Inc.ย (NASDAQ: TGTX),ย today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in ... Seite 1
May 31, 2023
The neurological disease affects approximately 2.8 million people worldwide - News - PharmaTimes
May 31, 2023
Frexalimab, a Sanofi drug candidate with roots at Dartmouthโs medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
May 30, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 30, 2023
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in June 30.05.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in June NEW YORK,...
May 30, 2023
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in June 30.05.2023 / 12:30 CET/CEST The issuer is solely responsible